| 10.22 -0.12 (-1.16%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.54  |
1-year : | 14.65 |
| Resists | First : | 10.73 |
Second : | 12.54 |
| Pivot price | 9.22 |
|||
| Supports | First : | 8.58 |
Second : | 7.26 |
| MAs | MA(5) : | 10.07 |
MA(20) : | 8.91 |
| MA(100) : | 8.83 |
MA(250) : | 8.5 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 84.7 |
D(3) : | 85.8 |
| RSI | RSI(14): 70.6 |
|||
| 52-week | High : | 11.97 | Low : | 6.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed below upper band by 16.7%. Bollinger Bands are 50.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.75 - 10.8 | 10.8 - 10.84 |
| Low: | 9.92 - 9.99 | 9.99 - 10.03 |
| Close: | 10.12 - 10.23 | 10.23 - 10.29 |
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Sun, 06 Sep 2026
GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Sat, 05 Sep 2026
NVAX Form 4 Filings - Novavax Inc SEC Form 4 - Stock Titan
Sat, 05 Sep 2026
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Fri, 04 Sep 2026
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Wed, 19 Aug 2026
Novavax (NVAX) Shares Skyrocket, What You Need To Know - Yahoo Finance
Thu, 06 Aug 2026
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 143 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 69 (%) |
| Shares Short | 45,660 (K) |
| Shares Short P.Month | 45,810 (K) |
| EPS | -1.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.16 |
| Profit Margin | -59.9 % |
| Operating Margin | -89.7 % |
| Return on Assets (ttm) | -6.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -76.4 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 2.5 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | 153 (M) |
| PE Ratio | -6.68 |
| PEG Ratio | 1.3 |
| Price to Book value | -8.82 |
| Price to Sales | 4.07 |
| Price to Cash Flow | -45.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|